8 active not recruiting, 4 completed, 2 recruiting, 1 not yet recruiting. 16 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Active not recruiting 8, Completed 4, Recruiting 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 1 | 5 | Recruiting 2, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1 |
Follow Recurrent Ewing Sarcoma: new trials by email Literature Review of Recurrent Ewing Sarcoma trials Research Report on Recurrent Ewing Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat Archive Sample Retrieval, Biospecimen Collection, pH Low Insertion Peptide-exatecan Conjugate CBX-12 - Recurrent Childhood Ewing Sarcoma, Recurrent Childhood Malignant Solid Neoplasm | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 79 | 2027-05-07 | 2026-09-22 |
| Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors Elimusertib - Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 31 | 2021-12-22 | 2026-01-23 |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint - Colorectal Carcinoma, Endometrial Carcinoma | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 147 | 2021-11-08 | 2026-08-25 |
| Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma Fine-Needle Aspiration, Irinotecan, Irinotecan Hydrochloride - Metastatic Ewing Sarcoma, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2021-09-15 | 2022-02-10 | |
| Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma Onivyde, Talazoparib, Temozolomide - Recurrent Solid Tumor, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 90 | 2021-06-09 | 2026-05-19 |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-10-09 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-10-16 |
| Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Ivosidenib - Recurrent Ependymoma, Recurrent Ewing Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 3 | 2020-07-20 | 2026-07-01 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-11-14 | 2026-09-21 |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2017-11-28 | 2026-04-21 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Tazemetostat - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2017-11-13 | 2026-04-13 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-07-24 |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Cabozantinib, Cabozantinib S-malate, Pharmacological Study - Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 109 | 2017-05-18 | 2026-08-28 |
| Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma Cabozantinib S-malate, Laboratory Biomarker Analysis - Metastatic Ewing Sarcoma, Metastatic Osteosarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 90 | 2014-12-19 | 2026-08-18 |
| Trabectedin and Irinotecan for Refractory Pediatric Sarcomas Combined chemotherapy with trabectedin followed by irinotecan - Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma | Unknown | Technical University of Munich | 30 | 2014-02-01 | 2015-07-27 | |
| Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors trabectedin, pharmacological study - Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma | Phase 2 | Completed | Children's Oncology Group | 50 | 2008-01-01 | 2018-09-14 |
Sarcoma, Ewing (17) · Osteosarcoma (12) · Rhabdomyosarcoma (12) · Hepatoblastoma (11) · Sarcoma (11) · Wilms Tumor (11) · Neuroblastoma (10) · Neuroectodermal Tumors, Primitive, Peripheral (10) · Lymphoma, Non-Hodgkin (9) · Rhabdoid Tumor (9) · Ependymoma (8) · Glioma (8) · Histiocytosis, Langerhans-Cell (8) · Medulloblastoma (8) · Central Nervous System Neoplasms (4)
Neoplasms by Histologic Type (17) · Neoplasms, Bone Tissue (17) · Neoplasms, Connective Tissue (17) · Neoplasms, Connective and Soft Tissue (17) · Neoplasms (16) · Myosarcoma (13) · Neoplasms, Muscle Tissue (13) · Neoplasms, Germ Cell and Embryonal (12) · Neoplasms, Glandular and Epithelial (12) · Neoplasms, Nerve Tissue (12) · Neuroectodermal Tumors (12) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11) · Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Genetic Diseases, Inborn (11)
Phantoms, Imaging (4) · Specimen Handling (4) · X-Rays (4) · Magnetic Resonance Spectroscopy (3) · LY3023414 (2) · Nuclear Medicine Department, Hospital (2) · cabozantinib (2) · ivosidenib (2) · palbociclib (2) · selpercatinib (2) · tazemetostat (2) · tipifarnib (2) · ulixertinib (2) · Absorptiometry, Photon (1) · BAY 1895344 (1)
National Cancer Institute (NCI) (11) · Children's Oncology Group (3) · M.D. Anderson Cancer Center (1) · St. Jude Children's Research Hospital (1) · Technical University of Munich (1)
United States (14) · Puerto Rico (8) · Canada (4) · Australia (3) · France (1)
Andrea T Franson (1) · Antoine Italiano (1) · Christine A Pratilas (1) · Donald W Parsons (1) · Elizabeth D Alva (1) · Juan C Vasquez (1) · Kieuhoa T Vo (1) · Michael V Ortiz (1) · Rajen Mody (1) · Robert S Benjamin (1) · Sara Federico, MD (1) · Sarah B Whittle (1) · Srivandana Akshintala (1) · Stefan Burdach, Prof. (1) · Susan N Chi (1)
PMID 31401903, PMID 22088484, PMID 32078813, PMID 33591402, PMID 35353553, PMID 38935895, PMID 39298716, PMID 41166674, PMID 42686334, PMID 42853672, PMID 42867148
U10CA180886 (9), UM1CA228823 (3), U10CA098543 (1)